Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAROCCO: Cediranib and Olaparib vs. Paclitaxel in Ovarian Cancer
NCT03314740Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib, olaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Mario Negri Institute for Pharmacological Research. Started Jun 2017; status: completed.
02
Drugs
cediranibolaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03314740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03314740.